Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 3/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | ESR1 | P03372 | 8/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826346 | 1.00 | P4HB (0.51) | P4HBARCA12CA2CA3 | |
| SCHEMBL6864978 | 0.88 | P4HB (0.50) | P4HBARCA12CA2CA3 | |
| Propionic Acid SCHEMBL10764681 | 0.84 | P4HB (0.48) | P4HBARCYP19A1HSD17B14 | |
| SCHEMBL9063141 | 0.84 | KIF11 (0.59) | P4HBARCA12CA2CA3 | |
| SCHEMBL2786052 | 0.84 | KIF11 (0.59) | P4HBARCA12CA2CA3 | |
| SCHEMBL540294 | 0.82 | P4HB (0.51) | P4HBARCA12CA2CA3 | |
| SCHEMBL22749362 | 0.82 | P4HB (0.40) | P4HBARCYP19A1ESR1ESR2 | |
| SCHEMBL7710176 | 0.81 | HNF4A (0.42) | P4HBCA3CA6CA9CA14 | |
| 4-Cyanophenol SCHEMBL28162196 | 0.81 | CA3 (0.57) | P4HBARCA12CA2CA3 | |
| SCHEMBL229147 | 0.78 | EGLN2 (0.44) | CA12CA2CA3CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563606-B | Synthesis method of (R) -2- [4- (4-cyano-2-fluorophenoxy) phenoxy ] propionic acid | 湖南速博生物技术有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-109212110-B | Gas chromatography-mass spectrometry combined method for measuring three trace monohalogenated hydroxyl benzonitrile in river water | 丁立平 | 2021-05-11 | — | — | CN | claimed |
| CN-110563606-A | Synthesis method of (R) -2- [4- (4-cyano-2-fluorophenoxy) phenoxy ] propionic acid | 湖南速博生物技术有限公司 | 2019-12-13 | — | — | CN | claimed |
| CN-110283173-A | A kind of imide analog compounds and its preparation method and application | 济南大学 | 2019-09-27 | — | — | CN | claimed |
| CN-108774155-A | A kind of preparation method of the fluoro- 4- cyanophenols of 3- | 河北凡克新材料有限公司 | 2018-11-09 | — | — | CN | claimed |
| US-8945887-B2 | Whole cell biocatalyst | ZYRUS BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE I KG (DE) | 2015-02-03 | — | — | US | claimed |
| US-20130011890-A1 | WHOLE CELL BIOCATALYST | ZYRUS BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE I KG (DE) | 2013-01-10 | — | — | US | claimed |
| EP-2501807-A2 | WHOLE CELL BIOCATALYST | ZYRUS Beteiligungsgesellschaft mbH & Co. Patente I KG (DE) | 2012-09-26 | — | — | EP | claimed |
| EP-2338987-A1 | Whole cell biocatalyst | ZYRUS Beteiligungsgesellschaft mbH & Co. Patente I KG (DE) | 2011-06-29 | — | — | EP | claimed |
| WO-2011057820-A2 | WHOLE CELL BIOCATALYST | ZYRUS BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE I KG (DE) | 2011-05-19 | — | — | WO | claimed |
| US-20100258033-A1 | WOOD ADHESIVE AND METHOD OF PREPARING THEREOF | YANG GUANG | 2010-10-14 | — | — | US | claimed |
| EP-2236578-A1 | A NEW LUMBER ADHESIVE AND THE PREPARATION THEREOF | Yang, Guang (CN) | 2010-10-06 | — | — | EP | claimed |
| CN-122036560-A | Radioactive medical isotope18F-labeled norepinephrine analogue as well as preparation method and application thereof | 中国医学科学院阜外医院 | 2026-05-15 | — | — | CN | disclosed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-0220254-A1 | BENZONITRILES. | MERCK PATENT GMBH (DE) | 1987-05-06 | — | — | EP | disclosed |
| EP-0219143-A1 | Synergistic herbicidal compositions and methods of use | STAUFFER CHEMICAL COMPANY (US) | 1987-04-22 | — | — | EP | disclosed |
| WO-1986006372-A1 | BENZONITRILE | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-11-06 | — | — | WO | disclosed |
| WO-1985004874-A1 | ANISOTROPIC COMPOUNDS AND LIQUID CRYSTAL MIXTURES THEREWITH | MERCK PATENT GMBH (DE) | 1985-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | P4HB 3397/4885AR 207/4885CA12 3247/4885 |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | P4HB 396/4885AR 3082/4885CA12 3573/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P4HB 1848/4885AR 3195/4885CA12 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.